Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of PF-06826647 in moderate to severe ulcerative colitis
2019-003999-39Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ropsacitinib in autoimmune colitis (3 arms), sponsored by Pfizer. Primary endpoint: Endoscopic response at Week 8. Started Apr 2020; status: terminated.
02
Drugs
ropsacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-003999-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003999-39.